Helsinn out-licenses CINV drugs to Fosun Pharma

12 October 2021

Privately-held Swiss firm Helsinn Group has today announced today the signing of exclusive license and distribution agreements with a subsidiary of China’s Fosun Pharma effective from October 1, 2021 in the territory of Mainland China for Aloxi (palonosetron hydrochloride), Akynzeo (netupitant and palonosetron hydrochloride) and anamorelin.

Financial terms of the accord were not disclosed, but under the terms of the agreements, Helsinn will grant Fosun Pharmaceutical AG an exclusive license to distribute, promote, market, and sell the following products in the aforesaid territory:

Approved and developmental products:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK